Highline Capital Management

Network Bio develops a platform that serves as a centralized repository for clinical and molecular data. This enables researchers to identify patterns and correlations, facilitating precision medicine approaches for common human diseases.

Proscia Inc., established in 2014 and headquartered in Philadelphia, Pennsylvania, specializes in digital pathology informatics through its innovative cloud-based platform. This platform aids in routine pathology operations, enhances cancer diagnosis, and seeks to improve patient outcomes. By leveraging advanced computing technologies, Proscia's solution unlocks hidden data that is not discernible to the human eye, transforming that information into valuable insights. These insights support physicians in accelerating the development of life-saving medical advances, ultimately contributing to a more effective diagnostic process in the field of pathology.

Proscia Inc., established in 2014 and headquartered in Philadelphia, Pennsylvania, specializes in digital pathology informatics through its innovative cloud-based platform. This platform aids in routine pathology operations, enhances cancer diagnosis, and seeks to improve patient outcomes. By leveraging advanced computing technologies, Proscia's solution unlocks hidden data that is not discernible to the human eye, transforming that information into valuable insights. These insights support physicians in accelerating the development of life-saving medical advances, ultimately contributing to a more effective diagnostic process in the field of pathology.

Strata Oncology, Inc. is a precision oncology company focused on enhancing cancer care by facilitating access to precision medicine clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, the company develops a comprehensive precision oncology platform that supports routine testing and efficient use of molecular data. Strata's offerings include The Strata Trial, a genomic testing program for systematic precision oncology implementation, and StrataNGS, a targeted assay for sequencing DNA and RNA from biopsies. Additionally, StrataPOINT integrates electronic medical record histories with molecular profiling to ensure eligible patients are tested and considered for trial enrollment. The company features a portfolio of pharma-sponsored therapeutic protocols, known as Strata Partnered Trials, aligned to specific biomarkers. Strata also operates The Strata Lab, a cancer sequencing facility, and maintains the Strata Precision Oncology Network, a collaborative entity aimed at promoting precision medicine initiatives. Formerly known as Strata Oncology Research, Inc., the company rebranded in 2016 and has been incorporated since 2015.

ATAI Life Sciences is a biotechnology company focused on developing therapies for mental health disorders, leveraging psychedelic compounds and neuroscience-based approaches. It operates a platform for mental health drug discovery and development and collaborates with partners and research institutions to advance its pipeline, which includes VLS-01, a buccal-film DMT candidate for treatment-resistant depression, and EMP-01, an oral MDMA therapy for social anxiety disorder, along with a drug discovery program aimed at identifying non-hallucinogenic 5-HT2A receptor agonists for depression. The company is based in Munich, Germany, with additional offices in Berlin and London.

Longboard Pharmaceuticals, Inc., established in 2020 and headquartered in San Diego, California, is engaged in developing optimized medicines targeting neurological diseases. The company focuses on improving pharmacology and pharmacokinetics to create novel treatments for rare conditions. Its pipeline includes LP352, a next-generation 5-HT2C agonist being evaluated for developmental and epileptic encephalopathies; LP143, a centrally acting CB2 receptor full agonist explored for potential treatment of neurological disorders like ALS and PD; and LP659, a highly selective S1P receptor modulator targeting multiple CNS neuroinflammatory disorders. Longboard operates as a subsidiary of Arena Pharmaceuticals, Inc., aiming to deliver these medicines to patients in need.

Passage Bio is a gene therapy company dedicated to developing transformative treatments for rare, monogenic central nervous system disorders. It has an integrated pipeline of five AAV-delivered therapeutics and collaborates with the University of Pennsylvania's Gene Therapy Program for preclinical work.